Michael Patrick Donovan - 16 Mar 2024 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
VP Operations
Signature
/s/ Marc Began by Power of Attorney for Mike Donovan
Issuer symbol
AXGN
Transactions as of
16 Mar 2024
Net transactions value
-$46,333
Form type
4
Filing time
25 Mar 2024, 21:22:54 UTC
Previous filing
08 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $0 +3,000 +8.4% $0.000000 38,708 16 Mar 2024 Direct F1
transaction AXGN Common Stock Sale $5,499 -716 -1.8% $7.68 37,992 21 Mar 2024 Direct F2
transaction AXGN Common Stock Options Exercise $0 +2,950 +7.8% $0.000000 40,942 16 Mar 2024 Direct F1
transaction AXGN Common Stock Sale $5,537 -721 -1.8% $7.68 40,221 21 Mar 2024 Direct F2
transaction AXGN Common Stock Options Exercise $0 +18,625 +46% $0.000000 58,846 16 Mar 2024 Direct F1
transaction AXGN Common Stock Sale $35,297 -4,596 -7.8% $7.68 54,250 21 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Restricted Stock Units Options Exercise $0 -3,000 -100% $0.000000* 0 16 Mar 2024 Common Stock 3,000 Direct F3, F4
transaction AXGN Restricted Stock Units Options Exercise $0 -2,950 -50% $0.000000 2,950 16 Mar 2024 Common Stock 2,950 Direct F3, F5
transaction AXGN Restricted Stock Units Options Exercise $0 -18,625 -50% $0.000000 18,625 16 Mar 2024 Common Stock 18,625 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael Patrick Donovan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This reflects the number of restricted stock units that became vested as of March 16, 2024.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.
F4 All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5 All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
F6 All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.